Company Presents Today at BioCentury Future Leaders Conference
SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) is providing an update today on the SGX523 clinical program.
In January 2008, the Company initiated two parallel, multi-center Phase 1 clinical trials of SGX523 in patients with solid tumor cancers. The first trial has been designed to examine twice daily, oral dosing on a continuous 28-day cycle and the second trial has been designed to examine interrupted dosing (a repeating 21 day cycle of 14 days on therapy followed by 7 days off).
In both trials, the Company observed dose limiting toxicity earlier than anticipated. The toxicity is of a nature that was not anticipated based on the preclinical profile of SGX523. The interrupted dosing trial started at a higher dose than the continuous dosing trial and no patients are currently receiving treatment on the interrupted dosing trial. In the continuous dosing trial, patients are continuing to be treated at a lower dose level, and the Company is evaluating the safety and efficacy of treatment at that dose level.
"From the initial clinical data, the profile of SGX523 appears to be
different than the preclinical data would suggest," said Mike Grey,
president and chief executive officer of SGX Pharmaceuticals. "On the
continuous dosing trial, patients continue on study at the initial dose and
we may explore whether alternative doses and schedules are safe and
efficacious. We continue the preclinical development of the BCR-ABL
inhibitor SGX393 and the second MET inhibitor SGX126. In addition, we are
targeting the identification of two development candidates this year from
our drug discovery programs to further enhance our pi
|SOURCE SGX Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved